Karim Helmy joined Venrock as a vice president in 2017 and focuses on healthcare investments across sectors and stages. He currently serves on the Board of Corvidia Therapeautics. Prior to joining Venrock, Karim was an Engagement Manager in the healthcare practice at McKinsey & Company where he worked with biopharma and device companies of all sizes focusing on clinical, regulatory and BD strategy. Earlier in his career, Karim worked at Genentech where he led a research effort that identified a novel immune receptor and advanced a molecule based on this discovery into pre-clinical development. Karim trained as a physician-scientist, earning MD/PhD degrees from New Jersey Medical School, where he where he graduated with Alpha Omega Alpha honors and received the Stanley S. Bergen, Jr. Medal of Excellence, awarded to the top graduating student in the class. He completed thesis research as a Howard Hughes Medical Institute Fellow at Memorial Sloan-Kettering Cancer Center studying gene regulation in primary brain tumors. He went on to complete an internship in Internal Medicine at Columbia University Medical Center. Karim received an undergraduate degree in Biological Sciences from Stanford University.